NO993943D0 - Kombinert tumorsuppressorgenterapi og kjemoterapi ved behandling av neoplasmer - Google Patents

Kombinert tumorsuppressorgenterapi og kjemoterapi ved behandling av neoplasmer

Info

Publication number
NO993943D0
NO993943D0 NO993943A NO993943A NO993943D0 NO 993943 D0 NO993943 D0 NO 993943D0 NO 993943 A NO993943 A NO 993943A NO 993943 A NO993943 A NO 993943A NO 993943 D0 NO993943 D0 NO 993943D0
Authority
NO
Norway
Prior art keywords
tumor suppressor
treatment
neoplasms
chemotherapy
combined tumor
Prior art date
Application number
NO993943A
Other languages
English (en)
Other versions
NO993943L (no
Inventor
Loretta Nielsen
Jo Ann Horowitz
Daniel C Maneval
William G Demers
Mary Ellen Rybak
Gene Resnick
Original Assignee
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canji Inc filed Critical Canji Inc
Publication of NO993943D0 publication Critical patent/NO993943D0/no
Publication of NO993943L publication Critical patent/NO993943L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Electrotherapy Devices (AREA)
NO993943A 1997-02-18 1999-08-17 Kombinert tumorsuppressorgenterapi og kjemoterapi ved behandling av neoplasmer NO993943L (no)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US80168197A 1997-02-18 1997-02-18
US80176597A 1997-02-18 1997-02-18
US3806597P 1997-02-18 1997-02-18
US80128597A 1997-02-18 1997-02-18
US80175597A 1997-02-18 1997-02-18
US4783497P 1997-05-28 1997-05-28
PCT/US1998/003514 WO1998035554A2 (en) 1997-02-18 1998-02-17 Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms

Publications (2)

Publication Number Publication Date
NO993943D0 true NO993943D0 (no) 1999-08-17
NO993943L NO993943L (no) 1999-10-15

Family

ID=27556335

Family Applications (1)

Application Number Title Priority Date Filing Date
NO993943A NO993943L (no) 1997-02-18 1999-08-17 Kombinert tumorsuppressorgenterapi og kjemoterapi ved behandling av neoplasmer

Country Status (19)

Country Link
EP (1) EP0969720B1 (no)
JP (1) JP2001511815A (no)
KR (2) KR100688409B1 (no)
CN (1) CN1248731C (no)
AT (1) ATE361668T1 (no)
AU (1) AU737621B2 (no)
BR (1) BR9807418A (no)
CA (1) CA2282683A1 (no)
CZ (1) CZ298488B6 (no)
DE (1) DE69837754T2 (no)
ES (1) ES2287974T3 (no)
HK (1) HK1026579A1 (no)
HU (1) HUP0004326A3 (no)
IL (2) IL131447A0 (no)
NO (1) NO993943L (no)
NZ (1) NZ337283A (no)
PL (1) PL193767B1 (no)
SK (1) SK285969B6 (no)
WO (1) WO1998035554A2 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524832B1 (en) 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
US7163925B1 (en) 1995-07-17 2007-01-16 Board Of Regents, The University Of Texas System p16 expression constructs and their application in cancer therapy
NZ313828A (en) 1995-07-17 1999-02-25 Univ Texas Expression constructs containing the encoding region of p16 and its regulatory elements and their application in cancer therapy e.g. a replication deficient adenviral vector containing p16
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
EP1760151B1 (en) 1996-11-20 2012-03-21 Crucell Holland B.V. Adenovirus compositions obtainable by an improved production and purification method
CO5080764A1 (es) * 1997-12-22 2001-09-25 Schering Corp Metodos para el tratamiento de enfermedades proliferativas
US6096757A (en) * 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
WO1999054445A2 (en) * 1998-04-22 1999-10-28 Inex Pharmaceuticals Corporation Combination therapy using nucleic acids and conventional drugs
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
WO2000056351A2 (en) * 1999-03-19 2000-09-28 Schering Corporation Combination use of gemcitabine and tumor suppressor gene therapy in the treatment of neoplasms
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
US6911200B2 (en) 2000-03-24 2005-06-28 Cell Genesys, Inc. Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation
US7048920B2 (en) 2000-03-24 2006-05-23 Cell Genesys, Inc. Recombinant oncolytic adenovirus for human melanoma
EP2241887B1 (en) * 2000-11-27 2015-01-14 Minerva Biotechnologies Corporation Diagnostics, drug screening and treatment for cancer
EP1340498A1 (en) * 2002-03-01 2003-09-03 Schering Aktiengesellschaft Use of epothilones in the treatment of brain diseases associated with proliferative processes
US7364727B2 (en) 2002-07-22 2008-04-29 Cell Genesys, Inc. Metastatic colon cancer specific promoter and uses thereof
CA2548220A1 (en) 2003-12-01 2005-09-09 Introgen Therapeutics, Inc. Use of mda-7 to inhibit infection by pathogenic organisms
AU2004305386A1 (en) * 2003-12-24 2005-07-07 Locomogene, Inc. Method of suppressing cancer
JPWO2005061007A1 (ja) * 2003-12-24 2007-07-12 学校法人 聖マリアンナ医科大学 癌の抑制方法
AU2005305347A1 (en) 2004-11-03 2006-05-18 Introgen Therapeutics Inc. Method of producing and purifying of adenoviral vectors
EP3256494A4 (en) 2015-02-10 2018-12-05 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
CN106692989A (zh) * 2017-03-07 2017-05-24 大连民族大学 一种药物脂质体/p53基因复合物及其制备方法和应用
CN109200295A (zh) * 2018-10-08 2019-01-15 蚌埠医学院 一种用于治疗卵巢癌的药物组合物及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
WO1995010514A1 (en) * 1993-10-15 1995-04-20 Schering Corporation Tricyclic sulfonamide compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
IL125062A (en) * 1995-12-22 2003-11-23 Schering Corp Tricyclic amides and pharmaceutical compositions containing them for inhibition of g-protein function and for treatment of proliferative diseases

Also Published As

Publication number Publication date
SK112299A3 (en) 2000-12-11
NO993943L (no) 1999-10-15
HUP0004326A3 (en) 2003-07-28
HUP0004326A2 (hu) 2001-02-28
PL335334A1 (en) 2000-04-25
KR100620939B1 (ko) 2006-09-06
EP0969720A2 (en) 2000-01-12
JP2001511815A (ja) 2001-08-14
HK1026579A1 (en) 2000-12-22
EP0969720A4 (en) 2004-05-12
CZ293399A3 (cs) 2000-03-15
NZ337283A (en) 2001-02-23
ES2287974T3 (es) 2007-12-16
PL193767B1 (pl) 2007-03-30
BR9807418A (pt) 2002-01-22
DE69837754D1 (de) 2007-06-21
CA2282683A1 (en) 1998-08-20
KR100688409B1 (ko) 2007-03-02
CN1252689A (zh) 2000-05-10
IL131447A0 (en) 2001-01-28
ATE361668T1 (de) 2007-06-15
IL195605A0 (en) 2011-08-01
EP0969720B1 (en) 2007-05-09
SK285969B6 (sk) 2007-12-06
WO1998035554A2 (en) 1998-08-20
AU6438098A (en) 1998-09-08
DE69837754T2 (de) 2008-02-07
WO1998035554A3 (en) 1998-11-26
CZ298488B6 (cs) 2007-10-17
KR20000071185A (ko) 2000-11-25
CN1248731C (zh) 2006-04-05
KR20050113287A (ko) 2005-12-01
AU737621B2 (en) 2001-08-23

Similar Documents

Publication Publication Date Title
IL195605A0 (en) Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
PT1157041E (pt) Anticorpos para terapia e diagnostico de cancro
EP1004022A4 (en) METHODS AND COMPOSITIONS FOR OVERCOMING RESISTANCE TO BIOLOGICAL THERAPY AND CHEMOTHERAPY
IL137164A0 (en) Enzyme catalyzed therapeutic agents
TR199902053T2 (xx) Prostat kanserinin immunoterapisine y�nelik bile�ikler ve bunlar�n kullan�lmas�na matuf metodlar.
DE69837529D1 (de) Proteinmarker für lungenkrebs und deren verwendung
CY1109367T1 (el) Συνθεσεις και μεθοδοι για ενισχυση της παροχης θεραπευτικων παραγοντων σε κυτταρα
ATE255632T1 (de) Immortalisierung bzw. desimmortalisierung von zellen
IL128872A0 (en) TNF-beta-like protein for treating prostate cancer and related nucleic acid molecules pharmaceutical compositions and methods
EP1011685A4 (en) METHOD OF TREATING CANCER USING ALKYLGLYCEROLS IN ASSOCIATION WITH CHEMOTHERAPY
DE69815840D1 (de) Verwendung von tall-104 zellen in kombination mit adriamyzin oder cisplatin zur behandlung von malignen tumoren
HUP9900011A2 (hu) A GAX protein alkalmazása rák kezelésére
BR0012301A (pt) Inibidores de crescimento de células epiteliais
WO2000056351A3 (en) Combination use of gemcitabine and tumor suppressor gene therapy in the treatment of neoplasms
ATE271878T1 (de) Verwendung von protein h als zytostattischer wirkstoff
CO5080825A1 (es) Sistema de terapia con genes suicidas para el tratamiento de tumores cerebrales
ATE308555T1 (de) Tumorsuppressormoleküle und nutzungsverfahren
EP1240922A3 (en) Methods and compositions for overcoming resistance to biologic and chemotherapy

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application